▼ -6.24% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Stoke Therapeutics in the last 3 months. The average price target is $44.38, with a high forecast of $68.00 and a low forecast of $30.00. The average price target represents a -6.24% upside from the last price of $47.33.
The current consensus among 9 contributing investment analysts is to buy stock in Stoke Therapeutics.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.